Ifezuntirgene inilparvovec

N/A

Report date: 2025/06/18 14:58:46

Base Information

Drug NameIfezuntirgene inilparvovec
Drug Alias NameAAV5-miSNP15AAV5-miSNP7AMT-130AAV5-miHtt12
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionGene silencingGene transferenceRNA interference +[5] 
TargetsGlial cell line-derived neurotrophic factorsBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsHuntington Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmsterdam Molecular TherapeuticsUniqure
China Registration ClassN/A

Develop Information

Active CompaniesUniqure Biopharma Bv
Inactive CompaniesN/A
Active IndicationsHuntington Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank